top of page
iStock-1329214856.jpg

Developing A Class Of Newly Discovered T-cells To Make Cell Therapies More Durable, Longer-lasting and Safer For Patients

RORABio is developing a first-in-class T-cell platform for targeting indications across cancer and infectious diseases. The platform consists of a newly discovered, long-lived, stem-like memory cell population that we call “RORA-Tscm”.  Since presence of RORA-Tscm cells correlates with reduced tumor burdens in animal models and is emerging as a hallmark of better clinical outcomes for some patients,     we are developing these cells in two formats: 1) modified with a mono- or bispecific chimeric receptor antigen (CAR) to make new CAR-T drugs with potential to be more durable, safer and long-lasting, and 2) as a stand-alone therapy to reconstitute the immune system of HIV infected patients.

iStock-1044548366.jpg
iStock-1265108955_edited_edited.jpg

Proprietary
Manufacturing Process

RORA-Tscm cells can be scalably expanded to homogeneity under GLP- and GMP-grade like conditions

Superior Stem-ness
and Durability

RORA-Tscm cells are associated with positive clinical outcomes in patients

Flexible T-cell Platform For Making New Cell Therapies

RORA-Tscm cells can be used alone or for making genetically engineered biologics (e.g., expressing a CAR or  edited/deleted gene) 

LATEST NEWS

August 15, 2023

South Africa is the epicenter of the worldwide HIV pandemic with about 20% of the population living with HIV. Despite availability of free anti-retroviral therapy (ART) has since 2004, and pre-exposure prophylaxis (PrEP) orals made part of healthcare guidelines since 2016, HIV/AIDS remains one of the most serious health concerns facing South Africa and the African continent.
For more information

bottom of page